CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery. 

The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for CoreValve versus 57.9% for medical treatment (p <0.0001). Cardiovascular mortality was 26.5% and mortality from all causes of 36.5%. The risk of stroke at 2 years was 5.1% but within the first year the biggest risk was concentrated with 4.3%, after first year the occurrence of the event was only 0.9%. 

92% of patients improved functional class at 2 years. No association between mild or moderate valvular insufficiency and mortality was observed. 

Conclusion 

2-year results confirm the improvement in survival of inoperable patients undergoing TAVR with self-expandable CoreValve. 

2_steven_yakubov
Steven J. Yakubov
2014-09-14

Original title: The CoreValve US Pivotal Trial: Two-Year Results with A Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis. 

More articles by this author

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the safety and efficacy of two vascular closure...

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the...

PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality,...

US CoreValve: Cost effectiveness of transcatheter replacement versus surgical replacement in high-risk patients

Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...